Canavan Disease: How Do Carrier and Prenatal Tests Work?

Planning another pregnancy after a child is diagnosed with Canavan disease can involve complex emotional and medical decisions. If you and your partner both carry a confirmed disease-causing variant in the ASPA gene, there is a 25% chance in each future pregnancy that the baby will inherit both variants and have the condition ^[1][2]. This 1-in-4 chance is independent for every pregnancy.

To accurately understand your risks, it is essential that a clinical geneticist or genetic counselor reviews your affected child’s genetic test report. They will verify that the specific disease-causing (pathogenic) variants have been identified, rather than “variants of uncertain significance” ^[1].

Understanding Carrier Status and Inheritance

Canavan disease is an autosomal recessive condition ^[3][4]. This means a child must inherit two disease-causing variants in the ASPA gene (one from each parent) to develop the disease. A person with just one disease-causing variant is a “carrier” and does not have symptoms.

If both you and your partner are confirmed carriers of the specific variants, the independent probabilities for each pregnancy are:

• A 25% chance the child will inherit two disease-causing variants and have Canavan disease ^[1][2].
• A 50% chance the child will inherit one variant, making them a carrier without the disease ^[1].
• A 25% chance the child will inherit two typical copies of the gene and be neither affected nor a carrier ^[1][2].

Before a subsequent pregnancy, both parents must be tested to confirm they carry the exact variants identified in their affected child ^[1]. If routine genetic testing does not identify both variants in a child with clinical symptoms, advanced testing (such as long-read sequencing) may be required to find hidden or complex genetic changes ^[3][4].

Options Before Pregnancy: IVF and Embryo Testing

For couples who know their specific familial variants, one preconception option is in vitro fertilization (IVF) with PGT-M (Preimplantation Genetic Testing for Monogenic disorders). “Monogenic” means the test looks for a condition caused by a single gene.

During IVF, embryos are created in a laboratory and tested for your family’s specific ASPA variants ^[5][6]. Unaffected embryos can then be selected for transfer. However, PGT-M has important limitations:

• It may require custom laboratory development that takes time.
• Some IVF cycles produce no embryos suitable for transfer ^[7].
• Testing relies on a very small sample and carries a small risk of misdiagnosis due to technical factors ^[8].
• It does not guarantee a successful pregnancy or a healthy baby, nor does it screen for all other possible genetic conditions.

Because residual risk remains, doctors often recommend confirmatory prenatal diagnostic testing during the pregnancy ^[8][9].

Options During Pregnancy: Prenatal Diagnosis

Routine prenatal screening (like ultrasound, maternal serum screening, or standard cell-free DNA/NIPT) does not rule out Canavan disease. To diagnose Canavan disease before birth, a targeted diagnostic test must look directly for the known familial ASPA variants.

If you conceive naturally or wish to confirm PGT-M results, the two main diagnostic procedures are:

• Chorionic Villus Sampling (CVS): Typically performed early in the pregnancy, between 10 and 13 weeks. A small sample of the placenta is tested ^[10][1]. While placental cells usually match the fetus, rarely they can differ (confined placental mosaicism), which might require follow-up amniocentesis for clarification ^[10].
• Amniocentesis: Usually performed later, at 15 weeks of pregnancy or beyond, by collecting and testing fetal cells from the amniotic fluid ^[11][10].

Both procedures carry a very small risk of additional procedure-related pregnancy loss above the natural background miscarriage rate. Large studies estimate this additional risk at roughly 0.2% for CVS and 0.3% for amniocentesis ^[12]. However, exact risks vary depending on the gestational age, the technique, and the specific medical center’s experience ^[10].

Post-Test Counseling and Options

If a prenatal test shows that a fetus is affected by Canavan disease, a genetic counselor and maternal-fetal medicine team will offer non-directive support to discuss your options. These may include continuing the pregnancy with advance pediatric and supportive-care planning, or, where legally available, pregnancy termination.

Newborn Testing

If you choose not to have prenatal testing, testing the baby for Canavan disease can be done after birth. However, Canavan disease is not routinely included in standard newborn screening panels in most regions. Targeted genetic testing for your family’s specific ASPA variants will need to be coordinated in advance with your pediatric and genetics team.

Ancestry and Carrier Screening

While Canavan disease can affect individuals of any background ^[13], people of Ashkenazi Jewish descent have a significantly higher carrier rate due to a “founder effect”—where a specific genetic variant becomes more common in a historically isolated population ^[14]. Professional medical guidelines, such as the 2025 position statement from the Canadian College of Medical Geneticists, recommend routine reproductive carrier screening for these specific founder variants ^[15].

However, standard ancestry-based screening panels look only for common founder variants and can miss rare ones ^[13]. A negative standard carrier screen does not entirely rule out being a carrier. If you already have a child with Canavan disease, you need targeted testing for your family’s specific variants or comprehensive ASPA analysis, regardless of your ancestry.